Home | Medical Dictionary | Contact Us         
 
 
  • About
    Cedars-Sinai
  • Careers at
    Cedars-Sinai
  • Giving
    & Support
  • Health
    Conditions
  • Healthcare
    Professionals
  • Patients
    & Visitors
  • Programs
    & Services
  • Quality
    Measures
  • Research &
    Education
  • Programs and Services
  • Cedars-Sinai Heart Institute
  • About Us
  • Anatomy of the Heart
  • Cardiothoracic Surgery Services
  • Cardiovascular Intervention Center
  • Clinical Trials
  • Arrhythmia Clinical Trials
  • Cardiac Imaging Clinical Trials
  • Congestive Heart Failure Clinical Trials
  • Core Labs
  • Coronary Artery Disease Clinical Trials
  • Dyslipidemia Clinical Trials
  • Genetic Studies
  • Heart Transplant Clinical Trials
  • Heart Valve Clinical Trials
  • Patent Foramen Ovale Clinical Trials
  • Pediatric Cardiology Clinical Trials
  • Postoperative Acute Management Clinical Trials
  • Women's Health Clinical Trials
  • Conditions of the Heart
  • Contact Us
  • Diagnostic Procedures
  • Drug Therapy
  • For Patients
  • For Physicians
  • Frequently Asked Questions
  • Glossary
  • In the News
  • Managing Risk Factors
  • Noninvasive Cardiac Laboratory
  • Our Expert Team
  • Preventive and Rehabilitative Cardiac Center
  • Research and Outcomes
  • Treatments/Programs
 
Patent Foramen Ovale Clinical Trials

Cedars-Sinai Heart Institute is currently conducting the following patent foramen ovale clinical trials:

  • The Study Comparing Implant Closure of a Heart Defect called Patent Foramen Ovale (PFO) to Traditional Medical Therapy. "CLOSURE 1"


The Study Comparing Implant Closure of a Heart Defect called Patent Foramen Ovale (PFO) to Traditional Medical Therapy. "CLOSURE 1"

Co-Investigator: Saibal Kar, MD
Principal Investigators: Ravinder Singh, MD

IRB Approval Number: 4133

Contact:Mitch Gheorghiu (310) 423-6152

Recruiting

Summary: The purpose of the Study is to compare the investigational defect closure device (StarFlex) to conventional medical treatment in preventing Stoke or TIA (transient ischemic attack), associated with a heart defect called PFO. The study population includes patients who experienced an index event Stoke or TIA in the previous 6 months, and also have had evidence (by echocardiography) of a PFO. The primary objective is to determine whether the Study device will safely and effectively prevent a recurrent embolic Stoke /TIA and to compare these with that of the best medical treatment (aspirin and the blood thinner: warfarin).

Back to Top

 
Cedars-Sinai Logo

© Copyright 2000-2008 Cedars-Sinai Health System.
All rights reserved.
Privacy Policy Terms and Conditions